Study guide
10.1 Detecting Events, AESIs and Collection Windows
ACRP CCRA Certified Clinical Research Associate Study Guide 2026 Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Format, Eligibility and Registration
1.1 Exam Format, Eligibility and Current References 1.2 Registration, Fees and Candidate Decisions
2 Chapter 2: CRA Responsibilities and Study Planning
2.1 The CRA Role, Data Integrity and Product Oversight 2.2 Official Blueprint and Study Strategy
3 Chapter 3: Protocols, Endpoints and Trial Design
3.1 Protocol Elements and Endpoint Hierarchy 3.2 Endpoint Interpretation and Eligibility Rationale 3.3 Eligibility Verification and Trial Designs
4 Chapter 4: Bias Control, Blinding and Product Information
4.1 Bias, Randomisation and Comparator Controls 4.2 Unblinding and Investigator Brochure Content 4.3 Reference Safety Information and IB Updates
5 Chapter 5: Estimands and Device Instructions
5.1 Estimands and Intercurrent Events 5.2 Device Instructions, Configuration and Training
6 Chapter 6: Ethical Foundations and Independent Oversight
6.1 Ethical Foundations and the 2024 Declaration of Helsinki 6.2 Vulnerability, Voluntariness and Compensation 6.3 IRB/IEC Composition and Independent Review
7 Chapter 7: Ethics Communication and Informed Consent
7.1 Ethics Reporting, Approval Status and Version Control 7.2 Informed Consent Information and Meaningful Choice 7.3 Consent Documentation, Special Circumstances and Updates
8 Chapter 8: Recruitment, Retention and Confidentiality
8.1 Ethical Eligibility, Recruitment and Retention 8.2 Privacy, Confidentiality and Appropriate Access
9 Chapter 9: Safety Definitions and Classification
9.1 Adverse Event Definitions and Actual Life-Threatening Risk 9.2 Seriousness, Severity and Medical Importance 9.3 Causality, Expectedness and Reference Safety Information
10 Chapter 10: Safety Detection, Reporting and Oversight
10.1 Detecting Events, AESIs and Collection Windows 10.2 Expedited Reporting and the Sponsor Awareness Clock 10.3 Immediate Site Reporting and Independent Safety Oversight
11 Chapter 11: Follow-Up, Adherence and Conflicts
11.1 Safety Communications, Reconciliation and Follow-Up 11.2 Adherence, Discontinuation and Participant Choice 11.3 Conflicts of Interest and Prorated Payments
12 Chapter 12: Development Stages and Product Management
12.1 Nonclinical Background and Human Pharmacology 12.2 Exploratory, Confirmatory and Therapeutic-Use Studies 12.3 Product Storage, Labelling and Excursion Response
13 Chapter 13: Accountability, Integrity and Regulatory Status
13.1 Product Accountability and Adherence Calculations 13.2 Potential Fraud, Misconduct and Evidence Preservation 13.3 Submissions, Authorisation Status and Trial Reporting
14 Chapter 14: Current GCP Principles and Delegation
14.1 The Eleven Current GCP Principles 14.2 Proportionality and Investigator Oversight 14.3 Delegation, Qualifications and Task Authority
15 Chapter 15: Oversight, Protocol Control and Amendments
15.1 Clinical Oversight and Immediate-Hazard Changes 15.2 Deviation Classification and Resolution
16 Chapter 16: Implementation and Trial Responsibilities
16.1 Amendment Implementation and Communication 16.2 Sponsor, Investigator and Service-Provider Roles
17 Chapter 17: Quality Planning, Root Causes and CAPA
17.1 Quality Planning and Risk Management 17.2 Root Cause Analysis and CAPA Design 17.3 CAPA Implementation and Effectiveness Verification
18 Chapter 18: Risk Assessment and Monitoring Methods
18.1 Risk Assessment and Centralised Surveillance 18.2 Monitoring Methods and Source Review
19 Chapter 19: Quality Metrics, Plans and Communication
19.1 KRIs, Acceptable Ranges and Trial-Level Quality 19.2 Monitoring Plans, Co-Monitoring and Communication
20 Chapter 20: Site Qualification and Readiness
20.1 Site Qualification and Investigator Capacity 20.2 Recruitment Feasibility and Evidence-Based Site Selection 20.3 Site Readiness and Activity-Specific Release
21 Chapter 21: Initiation, Equipment and Supplies
21.1 Initiation Training and Readiness Walkthroughs 21.2 Equipment, Maintenance and Study Supplies
22 Chapter 22: Samples, Diagnostics and Financial Feasibility
22.1 Specimens, Diagnostic Results and Rater Quality 22.2 Contracts, Budgets and Operational Feasibility
23 Chapter 23: Interim Monitoring and Reporting
23.1 Interim Visit Preparation and Consent Review 23.2 Monitoring Eligibility, Safety and Products 23.3 Investigator Debrief and Monitoring Reports
24 Chapter 24: Essential Records, Audits and Findings
24.1 Essential Records and Site/Sponsor Reconciliation 24.2 Version History, Resolution Evidence and Noncompliance 24.3 Audits, Inspections and Closure Planning
25 Chapter 25: Close-Out, Retention and Destruction
25.1 Close-Out, Archiving and Continuing Obligations 25.2 Retention, Destruction and Long-Term Access
26 Chapter 26: Source Records and Good Documentation
26.1 Source Records and Foundational ALCOA Principles 26.2 Good Documentation, Completeness and Corrections 26.3 Source Access, Certified Copies and Context
27 Chapter 27: Electronic Systems, Metadata and Queries
27.1 EDC Design and Fit-for-Purpose Systems 27.2 Audit Trails, Electronic Outcomes and Device Choice 27.3 Queries, Coding and Supported Clinical Meaning
28 Chapter 28: Dataset Finalisation and Critical Data
28.1 Safety Reconciliation and Dataset Finalisation 28.2 Critical Data, Acquisition Tools and Interim Findings
10.1 Detecting Events, AESIs and Collection Windows
Key Takeaways Explain This Topic AI
A medication change can signal a possible event but does not prove a diagnosis.
An AESI can be serious or non-serious and follows protocol-specific surveillance instructions.
Pre-dose events may require collection under the protocol.
Last updated: October 2026
Detecting Events, AESIs and Collection Windows
On site during Interim Monitoring Visits (IMVs), verifying safety reporting is the CRA's highest-priority obligation. Site coordinators and investigators under administrative strain frequently fail to recognize or capture adverse events.
Proactive Detection of "Hidden" Safety Events
Experienced CRAs do not merely read the completed AE log; they actively hunt for unreported events across multiple source streams:
Concomitant Medication Logs: If a CRA notices that a subject was newly prescribed ondansetron (an antiemetic) or ciprofloxacin (an antibiotic), but the AE log contains no mention of nausea, vomiting, or infection, a potential discrepancy needs clarification. The CRA should verify the indication and investigator assessment, then follow the protocol collection rules.
Progress Notes & Emergency Room Records: Reviewing nursing notes or physician correspondence often reveals that a patient called the clinic reporting severe dizziness or spent 8 hours in an urgent care clinic.
Diagnostic and Laboratory Reports: Reviewing local and central laboratory reports for flagged high/low values. If a participant's creatinine jumped from 0.9 mg/dL to 2.8 mg/dL, the CRA must verify that the investigator reviewed the report, documented clinical significance, and logged an AE for acute renal insufficiency if clinically meaningful.
Protocol-Mandated Dosing Adjustments: If an investigational product dose was withheld, reduced, or interrupted, the CRA must cross-reference the dose change against the AE log to ensure the underlying toxicity was documented.
Reviewing reporting timeliness
Reconstruct the sequence from the first site notification, investigator awareness, initial sponsor report and subsequent follow-up. Apply E6(R3)'s immediate reporting expectation and the trial's specific instructions. If a protocol specifies 24 hours, test that requirement; do not teach it as an ICH-defined universal limit. Review any protocol-defined exceptions and verify that they actually cover the event. A serious event does not become exempt because the investigator thinks it unrelated.
A medication change or abnormal result is a signal for investigator review, not proof of an AE diagnosis. A new antibiotic could represent prophylaxis; an abnormal laboratory value could be artefactual. Ask a neutral clarification question and verify the investigator's assessment. Do not direct the coordinator to invent an event merely to populate an empty log.
AESIs, pregnancy and collection windows
An AESI is a protocol-defined focus of surveillance and can require rapid communication or extra information even when it does not meet seriousness criteria. It does not automatically mean SUSAR. Evaluate seriousness, suspected relationship and expectedness separately while following the additional AESI instructions. A named risk in a safety plan can be important without being an expected adverse reaction in the designated RSI.
Pregnancy exposure is another situation that may have a separate protocol reporting and follow-up process. Pregnancy itself is not automatically an adverse event or a congenital anomaly. Record the required exposure and outcome information under the authorised process, protecting confidentiality. An adverse pregnancy outcome or other event may meet AE or seriousness criteria and needs the appropriate clinical assessment.
Do not wait for an eventual outcome to report an exposure when the protocol requires earlier notification.
The protocol defines relevant collection periods, including screening and post-treatment follow-up as appropriate. E6(R3) explicitly recognises consideration/reporting of unfavourable events before product administration if required by the protocol. A site should not omit a screening event solely because the person has not received a first dose. Conversely, a monitor should not invent an unlimited collection period beyond the agreed framework. Establish the timing, requirement and medical assessment from evidence.
Expedited Safety Reporting, SUSARs & Safety Oversight
Note
The expedited reporting of serious safety events represents the primary international mechanism for detecting emerging pharmacological risks, halting hazardous clinical investigations, and protecting human trial participants worldwide. Established under ICH E2A and operationalized through national regulatory frameworks (such as US FDA 21 CFR 312.32 and EU Clinical Trials Regulation 536/2014), strict safety escalation rules mandate that clinical trial sponsors, investigators, and monitors adhere to uncompromising timelines.
When an adverse event occurs during a clinical investigation, it enters a structured safety evaluation pipeline. While routine adverse events are captured in electronic case report forms (eCRFs) and evaluated during cumulative study analyses, safety occurrences that meet specific criteria require immediate, rapid escalation. On the CCRA examination, candidates must master the anatomical definition of a SUSAR , understand exact regulatory timelines (distinguishing calendar days from business days), grasp the independent role of Data Monitoring Committees, and execute rigorous monitoring oversight to reconcile clinical and safety databases.
Official sources
Checked October 18, 2026: ICH E6(R3), Principles and Annex 1 , ICH E2A , WMA Declaration of Helsinki, 2024 .